Will ALAB's non-GAAP OpEx remain below $120M in Q2 FY2026?

Q1 2026 OpEx guided at $112-118M. The step-function was driven by XScale acquisition (full quarter impact), Israel AQUI-hire, and expanded R&D. Q2 would be the second full quarter of these costs plus any additional hires. The question is whether OpEx stabilizes at the Q1 level (~$115M) or continues growing. If employees grew 60% YoY in 2025 and the company is in 'now is the time to invest' mode, continued hiring in Q2 would push OpEx above $120M. However, the XScale and Israel costs may be mostly absorbed in Q1 with limited incremental impact in Q2. The new CFO may also impose some cost discipline. It's roughly a coin flip.

The OpEx trajectory is steep: $80M (Q3) → $96M (Q4) → $112-118M guided (Q1). That's a 20% Q/Q increase trend. If the same trend continues, Q2 would be ~$134-142M — well above $120M. However, the Q4-to-Q1 step was specifically driven by discrete events (acquisition, AQUI-hire) that don't repeat in Q2. Organic OpEx growth is probably more like 5-8% Q/Q, which would put Q2 at ~$118-127M. The midpoint of this range is right around $120-123M — making this a close call. The probability sits below 50% because the investment philosophy ('now is the time to invest') suggests continued aggressive spending.

This is genuinely uncertain. On one hand, the Q1 step-function was driven by specific acquisitions and hires that may not repeat. On the other hand, the company is in aggressive investment mode and headcount is growing rapidly. If Q1 OpEx comes in at the high end of guidance (~$118M), Q2 staying below $120M requires nearly zero growth — unlikely. If Q1 comes in at the low end (~$112M), Q2 below $120M only requires <7% growth — more achievable. The outcome depends heavily on where Q1 actually lands within its guidance range.

Management explicitly said 'now is the time to invest.' The company grew headcount 60% YoY in 2025 and shows no signs of slowing. The Israel design center, Scorpio X development, and optical R&D all require sustained investment. If Q1 OpEx is ~$115M and grows even 5% to Q2, that's ~$121M — above $120M. The investment thesis demands continued spending growth. Staying below $120M in Q2 requires either a pause in hiring or deliberate cost discipline from the new CFO.

The spending ramp trajectory ($80M → $96M → $112-118M) shows 20% Q/Q growth. Even if this slows to 5% Q/Q, Q2 hits ~$121M. The new CFO Desmond Lynch may bring some cost discipline, but it's unusual for a new CFO to cut spending in their first quarter when the company's stated strategy is aggressive investment. The base case is that OpEx exceeds $120M in Q2. Below $120M would require active intervention.

If the XScale acquisition and Israel AQUI-hire are one-time cost step-ups that are fully absorbed in Q1, Q2 OpEx could stabilize at the Q1 level (~$115M). But ongoing hiring, R&D projects, and Scorpio X development will add incremental costs. $120M is a close threshold. The slight lean toward NO (above $120M) reflects the company's stated investment philosophy and hiring trajectory.

Q1 guided $112-118M. Q2 will likely be similar or higher. The $120M threshold is right in the middle of the probable Q2 range. Management's aggressive investment stance suggests Q2 OpEx above $120M is more likely than below.

The threshold is very close to Q1 guidance. Whether OpEx stays below $120M depends on the pace of incremental hiring and R&D spending. With 60% headcount growth in 2025 and continued investment plans, staying below $120M is roughly a coin flip.

The base case is that OpEx continues growing from Q1's $112-118M range. If it grows even 3-5% Q/Q from the $115M midpoint, it reaches $118-121M — right at the $120M threshold. Slight lean toward exceeding $120M given the investment ramp.